155767-23-0

Basic information

• Product Name: Benzenemethanol, 3-bromo-a-[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-
• CAS NO: 155767-23-0
• Molecular Formula: C19H25BrO2Si
• Molecular Weight: 393.396
• Mol File: 155767-23-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 3-bromo-a-[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 3-bromo-a-[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-(155767-23-0)
• EPA Substance Registry System: Benzenemethanol, 3-bromo-a-[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-(155767-23-0)

Safety Data

• Hazardous Substances Data: 155767-23-0(Hazardous Substances Data)

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 65423-56-5 1-bromo-3-[(tert-butyldimethylsilyl)oxy]benzene 
• 591-20-8 3-Bromophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 108-36-1 1,3-dibromobenzene 
• 96013-95-5 3-(tert-butyl-dimethyl-sylanyloxy)benzaldehyde 
• 100-83-4 meta-hydroxybenzaldehyde 

Downstream Products

• 1258203-31-4 [3-(t-butyldimethylsilyl)oxyphenyl]-(3-bromophenyl)methanone 
• 1258203-01-8 [[3-(t-butyldimethylsilyl)oxyphenyl](3-bromophenyl)ketone]thiosemicarbazone 
• 1131456-28-4 [[(3-bromophenyl)](3-hydroxyphenyl)ketone]thiosemicarbazone 
• 168155-49-5 tert-butyldimethylsilyl 3-((αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-(tert-butyldimethylsilyloxy)benzyl)benzoate 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS

This present disclosure is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin L, cathepsin K, and/or cathepsin B, will be therapeutically useful.

Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L

A series of thiosemicarbazone analogs based on the benzophenone, thiophene, pyridine, and fluorene molecular frameworks has been prepared by chemical synthesis and evaluated as small-molecule inhibitors of the cysteine proteases cathepsin L and cathepsin B. The two most potent inhibitors of cathepsin L in this series (IC50 50 = 150.8 nM). Bromine substitution in the thiophene series results in compounds that demonstrate only moderate inhibition of cathepsin L. The two most active analogs in the benzophenone thiosemicarbazone series are highly selective for their inhibition of cathepsin L versus cathepsin B.

OPIOID COMPOUNDS

Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.